UK Markets closed

AstraZeneca PLC (AZN.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
7,400.00+129.00 (+1.77%)
At close: 5:02PM BST
Full screen
Previous close7,271.00
Open7,252.00
Bid7,404.00 x 0
Ask7,404.00 x 0
Day's range7,237.00 - 7,449.00
52-week range6,736.00 - 10,120.00
Volume2,632,950
Avg. volume3,055,780
Market cap97.143B
Beta (5Y monthly)0.19
PE ratio (TTM)41.86
EPS (TTM)176.80
Earnings date30 Apr 2021
Forward dividend & yield2.07 (2.80%)
Ex-dividend date25 Feb 2021
1y target est78.83
  • Motley Fool

    AstraZeneca's Vaccine Data Is Still Good Enough for U.S. Authorization

    AstraZeneca (NASDAQ: AZN) created some drama releasing interim COVID-19 vaccine results just days before the pharma was able to generate final results from the U.S.-based phase 3 study. In this video from Motley Fool Live, recorded on March 29, Fool.com contributors Brian Orelli and Keith Speights discuss the brouhaha, and what it means for AstraZeneca's long-term prospects. Brian Orelli: AstraZeneca reported a final data from its COVID-19 vaccine -- that it went from 79% efficacy at preventing symptomatic COVID-19 for the interim look and then at the final look it was 76%.

  • Moderna cuts UK COVID vaccine deliveries as pregnant women told mRNA jabs are safe
    Yahoo Finance UK

    Moderna cuts UK COVID vaccine deliveries as pregnant women told mRNA jabs are safe

    The Moderna jab, which works in a similar way to the Pfizer vaccine, uses synthetic messenger RNA (mRNA) technology that can be quickly tweaked to address new mutations of a virus.

  • Yahoo Finance Video

    'You can think of it like an annual flu shot': Doctor on possible COVID-19 booster shots

    Assistant Professor of Emergency Medicine at Baylor College of Medicine, Dr. Sara Andrabi, joined Yahoo Finance to break down her thoughts on the possibility of needing annual COVID-19 booster shots to.